ADELAIDE, Australia, May 24, 2023 (GLOBE NEWSWIRE) — Carina Biotech (Carina), a cell therapy immuno-oncology company, today announced that the management team will be attending the three upcoming conferences as follows:
- 9th Annual Innovation Forum for Immuno-Oncology will be held in Chicago on June 2nd. Deborah Rathjen, Carina’s Chief Executive Officer, is expected to attend Competition in the field of cell and gene therapy Panel on June 2nd at 11:20am CT. The Carina team plans to host meetings and make presentations on Friday, June 2nd at 2:35pm CT.
- ASCO Annual Meeting 2023 takes place June 2-6 in Chicago in person and online. The Carina team will publish a poster presentation presenting the Phase 1/2a clinical trial of the LGR5-targeted CAR T-cell therapy candidate CNA3103 in patients with metastatic colorectal cancer (mCRC).
Poster Details
Title: A Phase 1/2a, Multicenter, Open-Label Trial of CNA3103 (LGR5-Targeting Autologous CAR-T Cells) in Patients With Metastatic Colon Cancer (mCRC)
Lead Author: José Iglesias, MD, Chief Medical Officer of Carina
Session Type/Title: Poster Session – Gastrointestinal Cancer – Colon and Anal Cancer
Session Date and Time: Monday, June 5, 2023 from 8:00 a.m. CDT to 11:00 a.m. CDT
Published abstract number: TPS3632
- 2023 BIO International Convention will be held in person in Boston from June 5th to 8th. The Carina team will hold meetings at the event.
About CNA3103
Carina’s proprietary CAR-T cell CNA3103 targets LGR5, a cancer stem cell marker that is highly expressed in advanced colorectal cancer and some other cancers. In colorectal cancer patients, LGR5 expression has been associated with poor prognosis. Cancer stem cells are a small subpopulation of cells within a tumor with the ability to self-renew, differentiate into the many cell types of a tumor, initiate new tumors, and resist (leading to relapse) chemotherapy and radiotherapy. By targeting cancer stem cells, it is hoped that this therapy will reduce the tumor’s ability to …
[ad_2]
Source story
